Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell therapy for ALS.

which indicates that MSCs might be a new strategy for the treatment of immune-mediated diseases. Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal stem cells that can be isolated ...

A multidisciplinary clinical team led by Professor Bernat Soria from the Institute of Bioengineering at the Miguel Hernández ...

An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF ...

Explore the advancements in stem cell therapy for neurodegenerative diseases. Discover market size, trends, and growth projections for 2035 with a focus on treatment innovations.

A new study in the peer-reviewed journal Stem Cells and Development highlights the potential of mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) as a therapeutic strategy for high-dose ...

Fibrobiologics' cell therapy CYMS101 significantly increased myelin production and promoted myelin repair in a mouse model of ...

The Department of Health - Abu Dhabi (DoH), has successfully completed a groundbreaking clinical trial in Abu Dhabi, in ...

Director, Paediatrics, Jaslok Hospital & Research Centre explains how stem cell therapy and regenerative medicine have the ...

Market Valued at US$ 1.69 Billion in 2024, Driven by Technological Advancements and Growing Healthcare Investments ...

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to ...